Late recurrence of breast cancer is associated with pro-cancerous immune microenvironment in the primary tumor.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
15 11 2019
Historique:
received: 01 08 2019
accepted: 28 10 2019
entrez: 16 11 2019
pubmed: 16 11 2019
medline: 11 11 2020
Statut: epublish

Résumé

The fact that 20-40% of all breast cancer (BC) patients develop recurrence when 5 year survival is 90% strongly suggests that late recurrence, i.e. more than 5 years after diagnosis, is the remaining challenge to decrease the absolute number of BC deaths. Better understanding late recurrence is an essential first step to address this issue. We hypothesized that primary tumors with a distinctive tumor immune microenvironment will develop late recurrence. Accordingly, we evaluated the relationship between the timing of cancer recurrence, clinical factors, gene expression profiles, and immune status utilizing two published large cohorts. 308 primary BCs in TCGA were analyzed and categorized as: recurrence ≤2 years (Early, n = 49), between 2-5 years (Mid, n = 54), recurrence >5 years (Late, n = 20), and no recurrence >5 years (Survivors, n = 185). 1,727 primary BCs in METABRIC were analyzed and categorized similarly: Early, n = 170; distant (D), n = 19; local (L), Mid, n = 213; D, n = 21; L, Late, n = 199; D, n = 57, L, and Survivors, n = 1048. Utilizing pre-ranked GSEA, we showed that primary tumors with Survivors were associated with anti-cancer signaling such as INF-α/-γ response and TNF-α signaling, compared with all recurrence groups in pre-ranked GSEA. Furtherrmore, we found that host defense immunity (leukocyte fraction, lymphocyte infiltration, and macrophage fractions) was decreased in primary tumors with Late recurrence compared with Survivors. Utilizing the CIBERSORT algorithm, we showed anti-cancer lymphocytes, memory CD4+ T cells and γδT cells, were significantly lower, and pro-cancerous regulatory T cells were significantly higher in Late tumors compared with Survivors. In agreement, cytolytic activity score that assesses immune cell cytolytic activity was significantly lower in Late compared with Survivors. We demonstrated that not only host defense immunity, but also pro-cancerous immune cells and immune cell cytolytic activity in primary BC was associated with late recurrence.

Identifiants

pubmed: 31729458
doi: 10.1038/s41598-019-53482-x
pii: 10.1038/s41598-019-53482-x
pmc: PMC6858361
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

16942

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016056
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA160688
Pays : United States

Références

Ann Surg Oncol. 2018 Aug;25(8):2323-2331
pubmed: 29770915
Clin Cancer Res. 2013 Dec 1;19(23):6389-97
pubmed: 24298069
Science. 2008 Jan 11;319(5860):195-8
pubmed: 18187653
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Clin Cancer Res. 2017 Jun 15;23(12):3129-3138
pubmed: 28007776
N Engl J Med. 2017 Nov 9;377(19):1836-1846
pubmed: 29117498
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
APMIS. 2008 Jul-Aug;116(7-8):648-59
pubmed: 18834409
Cell. 2018 Apr 5;173(2):400-416.e11
pubmed: 29625055
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2802-7
pubmed: 21908711
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
Nature. 2019 Mar;567(7748):399-404
pubmed: 30867590
Nature. 2007 Dec 6;450(7171):903-7
pubmed: 18026089
APMIS. 2008 Jul-Aug;116(7-8):685-94
pubmed: 18834412
Nat Commun. 2016 May 10;7:11479
pubmed: 27161491
Oncotarget. 2016 May 31;7(22):32504-18
pubmed: 27102299
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
PLoS Med. 2010 May 25;7(5):e1000279
pubmed: 20520800
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
PLoS One. 2012;7(4):e35569
pubmed: 22530051
Breast Cancer Res. 2015 Jan 27;17:10
pubmed: 25848913
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Clin Cancer Res. 2013 Dec 1;19(23):6398-403
pubmed: 24298070
Bioanalysis. 2019 Aug;11(15):1375-1377
pubmed: 31490108
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Oncotarget. 2017 Jun 14;8(32):52142-52155
pubmed: 28881720
J Clin Oncol. 2012 Mar 1;30(7):684-6
pubmed: 22271478
Breast. 2015 Nov;24 Suppl 2:S6-S10
pubmed: 26238437
J Soc Integr Oncol. 2008 Fall;6(4):158-68
pubmed: 19134448
J Natl Cancer Inst. 2013 Oct 2;105(19):1504-11
pubmed: 24029245
Nature. 2009 Oct 8;461(7265):809-13
pubmed: 19812674
Mol Cancer. 2018 Feb 26;17(1):67
pubmed: 29482551
Ann Oncol. 2007 Jan;18(1):45-51
pubmed: 17030545

Auteurs

Takashi Takeshita (T)

Breast Surgery, Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Li Yan (L)

Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Mariko Asaoka (M)

Breast Surgery, Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Omar Rashid (O)

Holy Cross Hospital, Trinity Health, Fort Lauderdale, FL, USA.
Massachusetts General Hospital, Boston, MA, USA.
University of Miami Miller School of Medicine, Miami, FL, USA.

Kazuaki Takabe (K)

Breast Surgery, Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. kazuaki.takabe@roswellpark.org.
Department of Surgery, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, the State University of New York, Buffalo, NY, USA. kazuaki.takabe@roswellpark.org.
Department of Breast Surgery and Oncology, Tokyo Medical University, Tokyo, Japan. kazuaki.takabe@roswellpark.org.
Department of Surgery, Yokohama City University, Yokohama, Japan. kazuaki.takabe@roswellpark.org.
Department of Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. kazuaki.takabe@roswellpark.org.
Department of Breast Surgery, Fukushima Medical University, Fukushima, Japan. kazuaki.takabe@roswellpark.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH